Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of GHK-Cu and Thymosin Alpha-1 — mechanism, side effects, legal status, and pricing.
GHK-Cu is the copper(II) complex of the human tripeptide glycyl-L-histidyl-L-lysine, first identified in human plasma by Loren Pickart in 1973. Plasma GHK declines with age. It is best established as a topical cosmetic ingredient for photoaged skin; it is NOT an FDA-approved drug in any jurisdiction.
Thymosin Alpha-1 (Tα1) is a 28-amino-acid acetylated peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN) corresponding to the N-terminus of prothymosin α. Marketed as Zadaxin / thymalfasin and approved in 35+ countries for chronic hepatitis B/C and as an immune adjuvant, but NOT FDA-approved in the US — Phase 3 HCV trials ended without approval. Outside the US it is one of the most clinically validated immune-modulating peptides.
GHK-Cu
Thymosin Alpha-1
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
GHK-Cu
Thymosin Alpha-1
COA corpus from Disclosed Labs — independently tested batches only.
GHK-Cu
215
COAs
99.6%
Avg purity
17
Labs
Thymosin Alpha-1
69
COAs
99.6%
Avg purity
12
Labs
GHK-Cu is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. Thymosin Alpha-1 remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
GHK was identified in human plasma by Pickart in 1973 and characterized as a copper-binding tripeptide in Nature in 1980 (PMID 7453802). Controlled topical studies in photoaged human skin have shown improvements in skin appearance and density with ~2% formulations. Pickart's 2014 review 'GHK and DNA: resetting the human genome to health' (PMID 25302294) and 2018 Int J Mol Sci review 'Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data' (PMID 29986520) summarize transcriptomic data showing modulation of thousands of genes involved in tissue repair, DNA repair, antioxidant defense, and anti-inflammation. The SubQ protocols circulating in the peptide community (typically 1-2 mg) are not supported by controlled human trials.
Key references
Thymosin alpha-1 has been studied in 90+ clinical trials. A meta-analysis by Yang et al. (Antiviral Research 2008, PMID 18078676) in chronic hepatitis B found antiviral efficacy comparable to interferon-alpha. Tuthill, Rios & McBeath (Ann N Y Acad Sci 2010, PMID 20536460) reviewed the global Zadaxin program across HBV, HCV, melanoma, HCC, and vaccine adjuvancy. Romani et al. (Blood 2006, PMID 16741252) established the TLR9 / IDO dendritic-cell mechanism that underlies Ta1's dual pro-inflammatory / tolerogenic effects. During the COVID-19 pandemic, Liu et al. (Clin Infect Dis 2020, PMID 32442287) reported reduced mortality (11.11% vs 30.00%, p=0.044) in severe lymphopenic COVID-19 patients via restoration of exhausted T cells. A 2024 systematic review by Dinetz & Lee (Altern Ther Health Med, PMID 38308608) covering 30+ trials and 11,000+ subjects concluded Ta1 is a well-tolerated and effective immune modulator, and argued the FDA's 2023 restriction appeared unfounded given the clinical evidence. US regulatory status: NOT FDA-approved; removed from 503A Category 2 in September 2024 after nominator withdrawal; PCAC voted AGAINST inclusion on the 503A Bulks List on December 4, 2024.
GHK-Cu (Cosmetic) and Thymosin Alpha-1 (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs